MedTrace Logo

A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome

NCT02611609 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-11-20

No results posted yet for this study

Summary

A study to examine the safety (and potential efficacy) of the adult stem cell investigational product, MultiStem, in adults who have Acute Respiratory Distress Syndrome (ARDS). The primary hypothesis is that MultiStem will be safe in ARDS patients.

Conditions

  • Acute Respiratory Distress Syndrome

Interventions

BIOLOGICAL

MultiStem

BIOLOGICAL

MultiStem

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • Athersys Limited

    collaborator INDUSTRY

  • Cell Therapy Catapult

    collaborator OTHER

  • Healios K.K.

    lead INDUSTRY

Principal Investigators

  • Geoff Bellingan, MD · University College London Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-09-30
Completion
2019-07-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02611609 on ClinicalTrials.gov